{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:31:31Z","timestamp":1794047491334,"version":"4.8.0"},"reference-count":40,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"3","license":[{"start":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T00:00:00Z","timestamp":1732147200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Chimeric antigen receptor (CAR) T cells targeting CD19 induce durable remissions in patients with relapsed or refractory non-Hodgkin lymphoma (NHL), but many patients experience treatment-related toxicity. Cytokine release syndrome and immune effector cell-associated neurologic syndrome are extensively characterized. However, limited data exist on the burden, predictors, and implications of acute kidney injury (AKI) after CAR T-cell therapy. On initial screening of the Food and Drug Administration adverse event reporting system, we identified a disproportionately high rate of renal adverse events among nearly 6,000 CAR T adverse event reports, suggesting it is clinically important in this patient population. In a subsequent single-center analysis of 399 NHL patients treated with CD19 CAR T cells, we found a substantial burden of AKI after CAR T infusion (10% and 5% of any grade and grade \u22652 AKI) with pre-renal causes being predominant (72%). Evolution to chronic kidney disease was rare, however, three patients required hemodialysis. Importantly, patients experiencing cytokine release syndrome and\/or neurotoxicity as well as those with low serum albumin and high inflammatory cytokines, including IL-6 and TNF-\u03b1, were more likely to develop AKI. While pre-CAR T renal dysfunction was not associated with adverse outcomes, patients developing post-CAR T AKI had lower overall survival compared to their counterparts. Our findings indicate that renal dysfunction is a common toxicity of CAR T-cell therapy with meaningful prognostic impact. Notably, the link between systemic inflammation and renal dysfunction, suggests that readily available biomarkers may inform on renal injury risk after CAR T-cell therapy.<\/jats:p>","DOI":"10.3324\/haematol.2024.286021","type":"journal-article","created":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T11:03:09Z","timestamp":1732186989000},"page":"651-664","source":"Crossref","is-referenced-by-count":6,"title":["Predictors and implications of renal injury after CD19 chimeric antigen receptor T-cell therapy"],"prefix":"10.3324","volume":"110","author":[{"given":"Alexander P.","family":"Boardman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Gutgarts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Flynn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean M.","family":"Devlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Goldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Alarcon","family":"Tomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua A.","family":"Fein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John B.","family":"Slingerland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"Parascondola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Scordo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parastoo B.","family":"Dahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Giralt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Lia","family":"Palomba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Salles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karthik","family":"Nath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moneeza","family":"Walji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Corona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae H.","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunjan L.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel-Angel","family":"Perales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Insara","family":"Jaffer-Sathick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roni","family":"Shouval","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2024,11,21]]},"reference":[{"key":"73165","doi-asserted-by":"crossref","unstructured":"Schuster SJ, Svoboda J, Chong EA. Chimeric antigen receptor T cells in refractory B-cell lymphomas. N Engl J Med. 2017; 377(26):2545-2554.","DOI":"10.1056\/NEJMoa1708566"},{"key":"73166","doi-asserted-by":"crossref","unstructured":"Neelapu SS, Locke FL, Bartlett NL. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017; 377(26):2531-2544.","DOI":"10.1056\/NEJMoa1707447"},{"key":"73167","doi-asserted-by":"crossref","unstructured":"Schuster SJ, Bishop MR, Tam CS. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019; 380(1):45-56.","DOI":"10.1056\/NEJMoa1804980"},{"key":"73168","doi-asserted-by":"crossref","unstructured":"Locke FL, Ghobadi A, Jacobson CA. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol. 2019; 20(1):31-42.","DOI":"10.1016\/S1470-2045(18)30864-7"},{"key":"73169","doi-asserted-by":"crossref","unstructured":"Abramson JS, Palomba ML, Gordon LI. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020; 396(10254):839-852.","DOI":"10.1016\/S0140-6736(20)31366-0"},{"key":"73170","doi-asserted-by":"crossref","unstructured":"Neelapu SS, Jacobson CA, Oluwole OO. Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma. Blood. 2020; 135(23):2106-2109.","DOI":"10.1182\/blood.2019004162"},{"key":"73171","doi-asserted-by":"crossref","unstructured":"Schuster SJ, Tam CS, Borchmann P. Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2021; 22(10):1403-1415.","DOI":"10.1016\/S1470-2045(21)00375-2"},{"key":"73172","doi-asserted-by":"crossref","unstructured":"Neelapu SS, Jacobson CA, Ghobadi A. Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma. Blood. 2023; 141(19):2307-2315.","DOI":"10.1182\/blood.2022018893"},{"key":"73173","doi-asserted-by":"crossref","unstructured":"Wang M, Munoz J, Goy A. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2020; 382(14):1331-1342.","DOI":"10.1056\/NEJMoa1914347"},{"key":"73174","doi-asserted-by":"crossref","unstructured":"Wang M, Munoz J, Goy A. Three-year follow-up of KTE-X19 in patients with relapsed\/refractory mantle cell lymphoma, including high-risk subgroups, in the ZUMA-2 study. J Clin Oncol. 2023; 41(3):555-567.","DOI":"10.1200\/JCO.21.02370"},{"key":"73175","doi-asserted-by":"crossref","unstructured":"Locke FL, Miklos DB, Jacobson CA. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N Engl J Med. 2022; 386(7):640-654.","DOI":"10.1056\/NEJMoa2116133"},{"key":"73176","doi-asserted-by":"crossref","unstructured":"Bishop MR, Dickinson M, Purtill D. Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma. N Engl J Med. 2022; 386(7):629-639.","DOI":"10.1056\/NEJMoa2116596"},{"key":"73177","doi-asserted-by":"crossref","unstructured":"Abramson JS, Solomon SR, Arnason J. Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study. Blood. 2023; 141(14):1675-1684.","DOI":"10.1182\/blood.2022018730"},{"key":"73178","doi-asserted-by":"crossref","unstructured":"Sehgal A, Hoda D, Riedell PA. Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study. Lancet Oncol. 2022; 23(8):1066-1077.","DOI":"10.1016\/S1470-2045(22)00339-4"},{"key":"73179","doi-asserted-by":"crossref","unstructured":"Westin JR, Oluwole OO, Kersten MJ. Survival with axicabtagene ciloleucel in large B-cell lymphoma. N Engl J Med. 2023; 389(2):148-157.","DOI":"10.1056\/NEJMoa2301665"},{"key":"73180","doi-asserted-by":"crossref","unstructured":"Perales MA, Anderson LD Jr, Jain T. Role of CD19 chimeric antigen receptor T cells in second-line large B cell lymphoma: lessons from phase 3 trials. An expert panel opinion from the American Society for Transplantation and Cellular Therapy. Transplant Cell Ther. 2022; 28(9):546-559.","DOI":"10.1016\/j.jtct.2022.06.019"},{"key":"73181","doi-asserted-by":"crossref","unstructured":"Kanate AS, Majhail N, DeFilipp Z. Updated indications for immune effector cell therapy: 2023 guidelines from the American Society for Transplantation and Cellular Therapy. Transplant Cell Ther. 2023; 29(10):594-597.","DOI":"10.1016\/j.jtct.2023.07.002"},{"key":"73182","doi-asserted-by":"crossref","unstructured":"Locke FL, Rossi JM, Neelapu SS. Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma. Blood Adv. 2020; 4(19):4898-4911.","DOI":"10.1182\/bloodadvances.2020002394"},{"key":"73183","doi-asserted-by":"crossref","unstructured":"Wudhikarn K, Pennisi M, Garcia-Recio M. DLBCL patients treated with CD19 CAR T cells experience a high burden of organ toxicities but low nonrelapse mortality. Blood Adv. 2020; 4(13):3024-3033.","DOI":"10.1182\/bloodadvances.2020001972"},{"key":"73184","doi-asserted-by":"crossref","unstructured":"Jacobson CA, Hunter BD, Redd R. Axicabtagene ciloleucel in the non-trial setting: outcomes and correlates of response, resistance, and toxicity. J Clin Oncol. 2020; 38(27):3095-3106.","DOI":"10.1200\/JCO.19.02103"},{"key":"73185","doi-asserted-by":"crossref","unstructured":"Rejeski K, Perez A, Sesques P. CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed\/ refractory large B-cell lymphoma. Blood. 2021; 138(24):2499-2513.","DOI":"10.1182\/blood.2020010543"},{"key":"73186","doi-asserted-by":"crossref","unstructured":"Gutgarts V, Jain T, Zheng J. Acute kidney injury after CAR-T cell therapy: low incidence and rapid recovery. Biol Blood Marrow Transplant. 2020; 26(6):1071-1076.","DOI":"10.1016\/j.bbmt.2020.02.012"},{"key":"73187","doi-asserted-by":"crossref","unstructured":"Kanduri SR, Cheungpasitporn W, Thongprayoon C. Systematic review of risk factors and incidence of acute kidney injury among patients treated with CAR-T cell therapies. Kidney Int Rep. 2021; 6(5):1416-1422.","DOI":"10.1016\/j.ekir.2021.02.013"},{"key":"73188","doi-asserted-by":"crossref","unstructured":"Wood AC, Perez AP, Arciola B. Outcomes of CD19-targeted chimeric antigen receptor T cell therapy for patients with reduced renal function including dialysis. Transplant Cell Ther. 2022; 28(12):829.e1-829.e8.","DOI":"10.1016\/j.jtct.2022.09.009"},{"key":"73189","doi-asserted-by":"crossref","unstructured":"Mozzicato P. Standardised MedDRA queries: their role in signal detection. Drug Saf. 2007; 30(7):617-619.","DOI":"10.2165\/00002018-200730070-00009"},{"key":"73190","doi-asserted-by":"crossref","unstructured":"Bate A, Evans SJ. Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol Drug Saf. 2009; 18(6):427-436.","DOI":"10.1002\/pds.1742"},{"key":"73191","doi-asserted-by":"crossref","unstructured":"Nor\u00e9n GN, Hopstadius J, Bate A. Shrinkage observed-to-expected ratios for robust and transparent large-scale pattern discovery. Stat Methods Med Res. 2013; 22(1):57-69.","DOI":"10.1177\/0962280211403604"},{"key":"73192","doi-asserted-by":"crossref","unstructured":"Harris PA, Taylor R, Minor BL. The REDCap consortium: building an international community of software platform partners. J Biomed Inform. 2019; 95:103208.","DOI":"10.1016\/j.jbi.2019.103208"},{"key":"73193","doi-asserted-by":"crossref","unstructured":"Inker LA, Eneanya ND, Coresh J. New creatinine- and cystatin C-based equations to estimate GFR without race. N Engl J Med. 2021; 385(19):1737-1749.","DOI":"10.1056\/NEJMoa2102953"},{"key":"73194","doi-asserted-by":"crossref","unstructured":"Lee DW, Santomasso BD, Locke FL. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019; 25(4):625-638.","DOI":"10.1016\/j.bbmt.2018.12.758"},{"key":"73195","doi-asserted-by":"crossref","unstructured":"Fabrizio VA, Boelens JJ, Mauguen A. Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy. [Erratum in Blood Adv. 2023 Jun 27;7(12):2924]. Blood Adv. 2022; 6(7):1961-1968.","DOI":"10.1182\/bloodadvances.2021006418"},{"key":"73196","doi-asserted-by":"crossref","unstructured":"Scordo M, Flynn JR, Gonen M. Identifying an optimal fludarabine exposure for improved outcomes after axi-cel therapy for aggressive B-cell non-Hodgkin lymphoma. Blood Adv. 2023; 7(18):5579-5585.","DOI":"10.1182\/bloodadvances.2023010302"},{"key":"73197","doi-asserted-by":"crossref","unstructured":"Langenhorst JB, Dorlo TPC, van Maarseveen EM. Population pharmacokinetics of fludarabine in children and adults during conditioning prior to allogeneic hematopoietic cell transplantation. Clin Pharmacokinet. 2019; 58(5):627-637.","DOI":"10.1007\/s40262-018-0715-9"},{"key":"73198","doi-asserted-by":"crossref","unstructured":"International Non-Hodgkin\u2019s Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin\u2019s lymphoma. N Engl J Med. 1993; 329(14):987-994.","DOI":"10.1056\/NEJM199309303291402"},{"key":"73199","doi-asserted-by":"crossref","unstructured":"Hammond DA, Smith MN, Li C, Hayes SM, Lusardi K, Bookstaver PB. Systematic review and meta-analysis of acute kidney injury associated with concomitant vancomycin and piperacillin\/ tazobactam. Clin Infect Dis. 2017; 64(5):666-674.","DOI":"10.1093\/cid\/ciw811"},{"key":"73200","doi-asserted-by":"crossref","unstructured":"Andronesi A, Sorohan B, Burcea A. Incidence and risk factors for acute kidney injury after allogeneic stem cell transplantation: a prospective study. Biomedicines. 2022; 10(2):262.","DOI":"10.3390\/biomedicines10020262"},{"key":"73201","doi-asserted-by":"crossref","unstructured":"Faramand RG, Lee SB, Jain MD. Baseline serum inflammatory proteins predict poor CAR T outcomes in diffuse large B-cell lymphoma. Blood Cancer Discov. 2024; 5(2):106-113.","DOI":"10.1158\/2643-3230.BCD-23-0056"},{"key":"73202","doi-asserted-by":"crossref","unstructured":"Levitt DG, Levitt MD. Human serum albumin homeostasis: a new look at the roles of synthesis, catabolism, renal and gastrointestinal excretion, and the clinical value of serum albumin measurements. Int J Gen Med. 2016; 9:229-255.","DOI":"10.2147\/IJGM.S102819"},{"key":"73203","doi-asserted-by":"crossref","unstructured":"Hunter BD, Hoda D, Nguyen A. Successful administration of chimeric antigen receptor (CAR) T-cell therapy in patients requiring hemodialysis. Exp Hematol Oncol. 2022; 11(1):10.","DOI":"10.1186\/s40164-022-00266-1"},{"key":"73204","doi-asserted-by":"crossref","unstructured":"Lin RJ, Owens CN, Drill E. Prephase rituximab\/prednisone therapy and aging-related, proinflammatory cytokine milieu in older, vulnerable patients with newly diagnosed diffuse large B-cell lymphoma. Haematologica. 2022; 107(5):1144-1152.","DOI":"10.3324\/haematol.2021.278719"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/11835\/77796","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11835\/78105","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11835\/77796","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:07:40Z","timestamp":1794046060000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/11835"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,21]]},"references-count":40,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2024.286021","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11,21]]}}}